Dyadic reports Q2 2026 results, cites commercial and C1 platform progress
The company disclosed a going-concern doubt alongside quarterly shipments, OEM and partner sales activity, and continued Gates Foundation and CEPI-backed antibody and vaccine antigen work.
Dyadic International reported financial results for the quarter ended June 30, 2026 on August 12, 2026. After quarter-end, the company completed shipments of six distinct recombinant protein products and generated initial pilot sales of recombinant transferrin and growth factors for cultivated-meat applications.1 It also initiated second-quarter shipments to IBT Bioservices under an OEM distribution agreement, with additional shipments completed after quarter-end to support product evaluation and commercialization.1
On partner programs, Proliant Health & Biologicals began commercializing Albufree DX recombinant human albumin and announced plans to expand the line with Albufree TX and Albufree CGT, which the company said positions Dyadic for future royalties.1 Inzymes confirmed initial commercial sales of non-animal bovine chymosin, with a second product in development that could trigger milestone payments and royalties.1
On global health work, Dyadic advanced Gates Foundation-funded RSV and malaria monoclonal antibody programs, with C1-produced antibodies showing productivity and functional characteristics comparable to mammalian-cell reference materials, and said funding is in place to move toward delivery of material to support initiation of preclinical studies.1 Separately, the company said C1 produced, purified and delivered two Scripps-designed Bundibugyo ebolavirus antigens to Scripps Research and Fondazione Biotecnopolo di Siena in about 15 days from plasmid to purified protein, with the antigens undergoing further characterization for possible future preclinical evaluation.1
On finances, cash, cash equivalents, restricted cash, and investment-grade securities including accrued interest totaled $4,794,798 as of June 30, 2026, down from $8,587,289 at December 31, 2025.1 The company said there is substantial doubt about its ability to continue as a going concern for the 12 months following June 30, 2026.1 Net loss for the quarter was $2,123,884, or $(0.06) per share, compared with $1,793,774, or $(0.06) per share, a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.